Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA.
Department of Neurosurgery, Tianjin Fifth Central Hospital, Tianjin, 300450, China.
Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4.
Tumor-infiltrating lymphocyte (TIL) therapy represents a groundbreaking advancement in the solid cancer treatment, offering new hope to patients and their families with high response rates and long overall survival. TIL therapy involves extracting immune cells from a patient's tumor tissue, expanding them ex vivo, and infusing them back into the patient to target and eliminate cancer cells. This revolutionary approach harnesses the power of the immune system to combat cancers, ushering in a new era of T cell-based therapies along with CAR-T and TCR-therapies. In this comprehensive review, we aim to elucidate the remarkable potential of TIL therapy by delving into recent advancements in basic and clinical researches. We highlight on the evolving landscape of TIL therapy as a prominent immunotherapeutic strategy, its multifaceted applications, and the promising outcomes. Additionally, we explore the future horizons of TIL therapy, next-generation TILs, and combination therapy, to overcome the limitations and improve clinical efficacy of TIL therapy.
肿瘤浸润淋巴细胞（TIL）治疗代表了实体瘤治疗的突破性进展，为高反应率和长期总生存率的患者及其家属带来了新的希望。TIL 治疗涉及从患者的肿瘤组织中提取免疫细胞，在体外扩增，并将其回输给患者，以靶向和消除癌细胞。这种革命性的方法利用免疫系统的力量来对抗癌症，开创了 T 细胞疗法以及 CAR-T 和 TCR-疗法的新时代。在这篇全面的综述中，我们旨在通过深入探讨基础和临床研究的最新进展，阐明 TIL 治疗的显著潜力。我们强调 TIL 治疗作为一种突出的免疫治疗策略的不断发展的前景，其多方面的应用和有前途的结果。此外，我们还探讨了 TIL 治疗、下一代 TIL 和联合治疗的未来前景，以克服 TIL 治疗的局限性并提高其临床疗效。
